Processing your request


please wait...

 | Case Page

 | Case Page |

Case Page

 

Gossamer Bio, Inc.

Case Summary

Gossamer Bio, Inc. Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 11/20/2020 (Date of last review)

Filing Date: April 03, 2020

According to the Complaint, Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company’s most advanced product is its GB001 drug, a DP2 antagonist, in development to treat asthma. In February 2019, Gossamer held its initial public offering (“IPO”) of common stock, selling approximately 19.8 million shares at $16.00 each.

The Complaint alleges that the materials supporting this offering, and certain of Gossamer’s post-IPO public filings, may have misled investors or otherwise omitted material facts relevant to Gossamer’s GB001 drug and its related clinical trials and studies.

On June 30, 2020, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on August 31. On November 20, Lead Plaintiff filed a second amended Complaint.

Company & Securities Information

Defendant: Gossamer Bio, Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: GOSS
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Scott Kuhne, et al. v. Gossamer Bio, Inc., et al.

COURT: S.D. California
DOCKET #: 20-CV-00649
JUDGE: Hon. Dana M. Sabraw
DATE FILED: 04/03/2020
CLASS PERIOD START: 02/08/2019
CLASS PERIOD END: 12/16/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Block & Leviton LLP (Boston)
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint for Violations of the Federal Securities Laws 04/03/2020
2 Order Granting Motion of Scott Kuhne for Appointment as Lead Plaintiff and Approval of Selection of Counsel 06/30/2020
3 U.S. District Court Civil Docket 07/17/2020

Reference Complaint

Scott Kuhne, et al. v. Gossamer Bio, Inc., et al.

COURT: S.D. California
DOCKET #: 20-CV-00649
JUDGE: Hon. Dana M. Sabraw
DATE FILED: 11/20/2020
CLASS PERIOD START: 02/08/2019
CLASS PERIOD END: 12/16/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Block & Leviton LLP (San Francisco)
Reference Complaint (REF) Filings:
No Document Title Filing Date
1 Amended Class Action Complaint for Violations of the Federal Securities Laws 08/31/2020
2 U.S. District Court Civil Docket 08/31/2020
3 Second Amended Class Action Complaint for Violations of the Federal Securities Laws 11/20/2020
4 U.S. District Court Civil Docket 01/06/2021

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases